Home Detox in Medication Overuse Headache (MOH) During Covid-19 Emergency
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Medication Overuse Headache (MOH) is a disabling condition that affects the 2% of migraine
population. Medication overuse (MO) makes this condition very difficult to treat. The
literature of the last decades confirm the efficacy of withdrawal for patients with
medication overuse, but it is also confirmed that patients have to be carefully followed
after withdrawal to avoid relapses and to improve the clinical benefit of the therapeutic
approach. Clinical results can be improved when traditional therapies are combined with
behavioral approaches in particular mindfulness, that help patient to become more conscious
about their symptoms and able to manage pain without medication. As the emergency situation
due to the Corona-virus pandemic phenomenon in Italy, the regular clinical practice adopted
for patients with CM-MO has changed in the last weeks: patients cannot come to the hospital
for the withdrawal iv therapy and for regular follow up as the reduced mobility due to the
emergency in particular in the Lombardia region, but all over Italy. So the investigators
propose a pilot study to enforce the application of a Home-program for the withdrawal
procedure for patients and the use of technology like smartphone and video calls so that
patients can continue to be followed in their therapeutic process by using behavioral support
and mindfulness practice. Patients will perform the withdrawal program at home, by oral
administration of therapies, with specific instructions and education. Also the information
for behavioral approach and mindfulness practice will be given, to use every day at home.
Daily standardized mindfulness sessions of 12 minutes on their smartphone will be combined
with weekly video-call to evaluate the clinical condition and to encourage the use strategies
for pain management. Face-to-face visits at the follow up every three months will be
scheduled. This modality will allow the patients to continue their therapeutic process and to
be regularly followed during the one year after withdrawal.
Phase:
N/A
Details
Lead Sponsor:
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta